This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gilead Swings to Profit, Names CFO

Gilead (GILD - Get Report) reported a 3-cent earnings beat, strong HIV franchise sales and a new CFO after Thursday's market close.

Net income for the third quarter was $398.3 million, or 42 cents a diluted share, including after-tax stock-based compensation expenses of $31.8 million, compared to a loss of 3 cents in the year-ago quarter. Analysts surveyed by Thomson Financial expected 39 cents a share on revenue of $1 billion.

Gilead reported total revenue of $1.1 billion and HIV product sales of $805.8 million in the third quarter of 2007, a 45% increase from $557.3 million for the same period in 2006. The increase was driven primarily by the sales volume growth in Truvada and Atripla (a single-pill combination of Truvada with Bristol-Myers Squibb's (BMY) Sustiva), and beat the Street consensus of $954 million for total product sales and $794 million for the HIV franchise.

Truvada sales were $409.1 million in the recent quarter (beating Street estimates of $390 million), an increase of 32% from $309 million in the third quarter of 2006. Truvada sales accounted for roughly 51% of Gilead's total HIV product sales and about 43% of the company's total product sales in the third quarter of 2007.

Atripla sales came in at $241.1 million (just lighter than the Street consensus of $241 million), compared to $68.4 million recorded in the third quarter of 2006, the drug's first quarter of sales in the U.S. Viread (also for HIV) sales increased 13% to $149.1 million.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AV $12.46 -1.50%
GILD $85.84 0.28%
MRK $54.09 -1.30%
AAPL $93.21 -0.44%
FB $117.80 -0.22%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs